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A B S T R A C T
Background: The ‘smoker’s paradox’ refers to the observation of favorable prognosis in current smokers
following an acute ST elevation myocardial infarction (STEMI) in the era of ﬁbrinolysis, however, several
STEMI studies have demonstrated conﬂicting results in patients undergoing primary percutaneous
coronary intervention (p-PCI).
Objective: Aim of the current study was to evaluate the impact of cigarette smoking on left ventricular
function in STEMI patients undergoing p-PCI.
Methods: Our population is represented by 74 ﬁrst-time anterior STEMI patients undergoing p-PCI, 37 of
whom were smokers. We assessed left ventricular function by left ventricular ejection fraction (LVEF) on
the second day after admission and at 3-month follow-up. Early predictors of adverse left ventricular
remodelling after STEMI treated by p-PCI were examined.
Results: Basal demographics and comorbidities were similar between groups. Although the LVEF during
the early phase was higher in smokers compared to non-smokers (44.95  7.93% vs. 40.32  7.28%;
p = 0.011); it worsened in smokers at follow-up (mean decrease in LVEF: 2.70  5.95%), whereas it
improved in non-smokers (mean recovery of LVEF: +2.97  8.45%). In univariate analysis, diabetes mellitus,
peak troponin I, current smoking, and lower TIMI ﬂow grade after p-PCI, pain-to-door time and door-to-
balloon times were predictors of adverse left ventricular remodelling. After multivariate logistic regression
analysis, smoking at admission, lower TIMI ﬂow grade after p-PCI, the pain-to-door time and door-to-balloon
times remained independent predictors of deterioration in LVEF.
Conclusion: True or persistent ‘smoker’s paradox’ does not appear to be relevant among STEMI patients
undergoing p-PCI. The ‘smoker’s paradox’ is in fact a pseudo-paradox. Further studies with larger
numbers may be warranted.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cigarette smoking (CS) remains the leading cause of prevent-
able cardiovascular morbidity and mortality in the world.1,2 It
impacts all phases of atherosclerosis from endothelial dysfunction
to acute thrombotic coronary syndromes.3 Despite these well-
known deleterious effect on cardiovascular health, some studies
have suggested a ‘‘smoker’s paradox’’ meaning neutral or better* Corresponding author at: Tu¨rkiye Yu¨ksek I˙htisas Hastanesi, Kardiyoloji Klinig˘i,
Ankara 06100, Turkey. Tel.: +90 505 383 67 73; fax: +90 312 306 1000.
E-mail address: ozcanozeke@gmail.com (O. Ozeke).
http://dx.doi.org/10.1016/j.ihj.2016.04.001
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).outcomes in current smokers following an acute ST elevation
myocardial infarction (STEMI) in the era of ﬁbrinolysis.4–8
However, multiple studies in smokers have yielded conﬂicting
results in STEMI patients undergoing primary percutaneous
coronary intervention (p-PCI).9–16 We aim to determine the
presence of a ‘smoker’s paradox’ in a cohort of ﬁrst-time anterior
STEMI patients undergoing p-PCI.
2. Method
We studied 74 consecutive Caucasian patients with ﬁrst ever
anterior STEMI, who underwent coronary angiography within 12 h open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Basal demographic and clinical characteristics features in ﬁrst anterior STEMI patients undergoing p-PCI.
Anterior STEMI patients undergoing p-PCI Smokers (n: 37) Non-smokers (n: 37) p value
Age (year, mean  SD) 54.68  8.03 58.81  11.05 0.070
Smoking pack-years 28.46  8.19 – NA
Gender (male, %) 78% 65% 0.197
Hypertension (%) 41% 46% 0.639
Diabetes mellitus (%) 27% 30% 0.797
Hyperlipidemia (%) 30% 35% 0.619
Premature family history for CAD (%) 22% 32% 0.295
Body mass index (mean  SD) 26.68  5.13 28.08  4.09 0.199
Pain-to-door time (h, median, IQR) 5 (2) 6 (5) 0.402
Door-to-balloon time (min, median, IQR) 38 (15) 38 (10) 0.904
TIMI 0–1 ﬂow grade before p-PCI (%) 100% 100% NA
TIMI 3 ﬂow grade after p-PCI (%) 88% 90% 0.862
Dual antiplatelet agents at 3 months post-discharge (%) 100% 100% NA
Beta blocker at 3 months post-discharge (%) 92% 95% 0.643
ACE-I/ARB at 3 months post-discharge (%) 100% 100% NA
Statin at 3 months post-discharge (%) 92% 97% 0.304
Furosemide at 3 months post-discharge (%) 22% 34% 0.295
Spirinolactone at 3 months post-discharge (%) 11% 19% 0.327
Peak troponin I (u’gr/L, median, IQR) 35 (14) 44 (20) 0.016
Killip class at admission (median, IQR) 1 (0) 1 (1) 0.141
Smoking quitting rate at 3 months post-discharge (%) 84% – NA
STEMI, ST elevation myocardial infarction; p-PCI, primary percutaneous coronary intervention; CAD, coronary artery disease; ACE-I/ARB, angiotensinogen converting enzyme
inhibitors/angiotensinogen receptor blockers; SD, standard deviation; IQR, interquartile range; NA, not applicable.
Fig. 1. Assessment of smoking status in STEMI patients predicts worsening of left
ventricular systolic function.
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p-PCI for acute total occlusion of single vessel left anterior
descending artery. Information about age, gender, body-mass
index, family history of premature coronary artery disease (male
ﬁrst degree relatives <55 years old and female ﬁrst degree relatives
<65 years old), dyslipidemia (high LDL-cholestrol based on ATP III
or HDL-cholestrol <40 mg/dL, or triglycerides >150 mg/dL),
diabetes mellitus (fasting blood glucose 126 mg/dL, 2 h post-
prandial glucose 200 mg/dL, or use of hypoglycemic agents or
insulin), hypertension (positive past history of hypertension or use
of antihypertensive drugs) and, CS consumption were collected.
The patients were categorized as active smokers or non-
smokers at the time of hospital admission. The previous smokers,
the previous history of STEMI and non-anterior STEMI patients
were excluded from the study because of their possible confound-
ing effect on results.
Univariate and multivariate analyses were performed to
identify predictors for adverse left ventricular remodelling, deﬁned
as a decrease in left ventricular ejection fraction (LVEF) at 3-month
follow-up compared with the baseline.
After primary PCI, the global LVEF was measured by an
experienced physician unaware of patient identity using transtho-
racic echocardiography (System V GE Vingmed Ultrasound,
Horton, Norway) at second hospitalization days and at 3 months
post-discharge period. The LVEF was measured using the modiﬁed
Simpson’s rule.17 All patients discharged with modern pharmaco-
logical treatment including beta-blockers, ACE-inhibitors or ARBs,
dual antiplatelet and statins. Adherence to evidence-based
medications was evaluated at post-discharge 3 months.
Written informed consent was obtained from all patients, and
the study protocol was approved by the ethics committee of the
hospital.
Statistical analyses were performed using Statistical Package for
Social Sciences (SPSS) for Windows 20 (IBM SPSS Inc., Chicago, IL).
We calculated that a sample size of 37 per group would be required
to achieve a desired power of 0.80 with an alpha value of
0.05. Normal distributions of variables were evaluated with
Kolmogorov–Smirnov test. Numerical variables with a normal
distribution were presented as the mean  standard deviation and
numerical variables with a skewed distribution were presented as the
median (interquartile range) and categorical variables were presented
as percentages (%). Two group comparisons of normally distributedvariables were tested by unpaired t test and paired t test. The
nonparametric Mann–Whitney U test was used for comparisons of
nonnormally distributed variables. Paired comparisons of nonnormally
distributed variables were analyzed by the Wilcoxon signed-rank test.
Chi square test and Fischer’s exact 2 test were used for comparisons of
categorical variables. Predictors of left ventricular remodelling were
determined by logistic regression analysis. All items with signiﬁcant
results in univariate analysis were included in multivariate analysis,
followed by a stepwise forward elimination. The strength of association
between variables and the occurrence of adverse left ventricular
remodelling were represented by odds ratios and their accompanying
95% conﬁdence intervals. For all tests, a two tailed p-value less than
0.05 was deﬁned statistically signiﬁcant.
3. Results
Basal demographics and comorbidities were similar between
groups (Table 1). Two patients in smokers group were excluded
from study because of periprocedural cardiac death. No adverse
cardiac adverse events including mortality or recurrence of angina
at 3 months post-discharge follow-up were detected.
Although the LVEF during the early phase was higher in smokers
compared to non-smokers (44.95  7.93% vs. 40.32  7.28%;
p = 0.011), it worsened in smokers at follow-up (mean decrease in
LVEF: 2.70  5.95%), whereas it improved in non-smokers (mean
recovery of LVEF: +2.97  8.45%) (Fig. 1, Tables 2 and 3).
Table 2
The comparison of the basal clinical and echocardiographic parameters taken at second days of hospitalization in both group.
Anterior STEMI patients undergoing p-PCI Smokers (n: 37) Non-smokers (n: 37) p value
Heart rate (beat per minute, mean  SD) 82.19  9.67 78.78  8.62 0.114
Systolic blood pressure (mmHg, median, IQR) 130 (20) 130 (35) 0.318
Diastolic blood pressure (mmHg, median, IQR) 80 (20) 80 (15) 0.431
Echocardiographic ﬁndings
LVEF (%) (mean  SD) 44.95  7.93 40.32  7.28 0.011
LVEDD (cm) (median, IQR) 4.8 (0.1) 4.9 (0.5) 23.08  4.55 0.007
SPAP (mmHg) (mean  SD) 25.08  4.91 0.073
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; SPAP, systolic pulmonary artery pressure; SD, standard deviation; IQR, interquartile
range.
Table 3
Comparison of the echocardiographic LVEF taken at second day of hospitalization and at post-discharge third month control.
Anterior STEMI patients undergoing p-PCI At second days hospitalization At post-discharge third months p value
Smokers; n = 37
Echocardiographic ﬁndings
LVEF (%) (mean  SD) 44.95  7.93 42.24  10.84 0.009
LVDD (cm) (median, IQR) 4.80 (0.2) 5.00 (0.5) 0.043
Heart rate (beat per minute, mean  SD) 82.19  9.67 78.81  10.94 0.077
Systolic blood pressure (mmHg, median, IQR) 130 (25) 125 (20) 0.010
Diastolic blood pressure (mmHg, median, IQR) 80(20) 75 (9) 0.001
SPAP (mmHg) at (mean  SD) 25.08  4.91 26.00  4.97 0.074
Mean change in LVEF (%) at post-discharge 3 months 2.70  5.95
Non-smokers; n = 37
Echocardiographic ﬁndings
LVEF (%) (mean  SD) 40.32  7.28 43.30  12.52 0.039
LVEDD (cm) (median, IQR) 4.90 (0.5) 5.10 (0.7) <0.001
Heart rate (beat per minute, mean  SD) 78.78  8.62 72.16  10.87 0.001
Systolic blood pressure (mmHg, median, IQR) 130 (35) 125 (20) <0.001
Diastolic blood pressure (mmHg, median, IQR) 80(15) 76 (11) <0.001
SPAP (mmHg) (mean  SD) 23.08  4.55 23.49  5.11 0.333
Mean change in LVEF (%) at post-discharge 3 months +2.97  8.45
STEMI, ST elevation myocardial infarction; p-PCI, primary percutaneous coronary intervention; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; LVEDD,
left ventricular end diastolic diameter; SPAP, systolic pulmonary artery pressure.
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reduction in LVEF was more prominent in those who continued
smoking compared to quitting smoking (mean decrease in LVEF:
2.00  5.39% in quitting smoking vs. 7.33  7.20% continued
smoking; p = 0.042).
In univariate analysis, diabetes mellitus, peak troponin I,
current smoking, the lower TIMI ﬂow grade after p-PCI, pain-to-
door time and door-to-balloon times were predictors of adverse
left ventricular remodelling. After multivariate logistic regression
analysis, smoking at admission, lower TIMI ﬂow grade after p-PCI,
the pain-to-door time and door-to-balloon time remainedTable 4
Univariate and multivariate predictors of adverse left ventricular remodelling.
Variable Univariate 
p OR 95% CI 
Age 0.339 
Male gender 0.466 
Hypertension 0.639 
Diabetes mellitus 0.041 3.06 1.05–8.96 
Dyslipidemia 0.940
Premature family history of CAD 0.170
Body mass index 0.332
Peak troponin I 0.034 1.03 1.00–1.06 
LVEF at admission 0.137
Current smoking at admission 0.028 2.92 1.12–7.58 
TIMI 0–2 ﬂow grade after p-PCI 0.001 7.50 2.17–25.91 
Killip classiﬁcation 0.122
Pain-to-door time 0.028 1.21 1.02–1.43 
Door-to-balloon time 0.001 1.15 1.05–1.25 
CAD, coronary artery disease; LVEF, left ventricular ejection fraction; p-PCI, primary peindependent predictors of deterioration in LVEF after STEMI
(Table 4).
4. Discussion
The results of our study suggest that the ‘smoker’s paradox’ is a
pseudo-paradoxs in STEMI patients undergoing p-PCI. Although
the LVEF during the early phase (in-hospital second days) was
higher in smokers compared to non-smokers; it worsened in
smokers at follow-up, whereas it improved in non-smokers.
Therefore, we speculated that true or persistent ‘smoker’s paradox’Multivariate
p OR 95% CI
1.7 –
1.9 – 0.000E
1.8 – 0.000E
0.127 2400 –
0.901
0.008 5.91 1.60–21.81
0.038 4.97 1.09–22.57
0.011 1.34 1.07–1.69
0.031 1.01 1.03–1.24
rcutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
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p-PCI.
Multiple studies in the past have shown that smokers, who
underwent PCI seem to have paradoxically better outcomes than
non-smokers.5,8,14,18,19 There has been some speculation regarding
mechanisms involved in the paradoxical effects of active CS
following p-PCI.10,14,19 Firstly, the PREMIAR (the protection of
distal embolization in high-risk patients with acute STEMI)
investigators reported that CS in STEMI patients undergoing p-
PCI was associated with better myocardial reperfusion than non-
smokers,20 and postulated that this may be the mechanism behind
the smoker’s paradox and its beneﬁcial effect in the short-term
clinical outcome. The other possible mechanisms might be a ‘pre-
conditioning’-like effect of nicotine, an active component of the CS
in early phase, but the CS might have a deleterious effect on cardiac
or ventricular remodelling in the late phase.21 Experimental and
clinical studies have shown the direct toxic effects of CS on the
myocardium, independent of vascular effects.22–24 Tobacco smoke
contains more than 4000 chemical compounds that might have an
effect on human coronary collaterals.25 In addition to smoking-
induced chronic hypoxia and endothelial dysfunction, nicotine was
shown to be a potent physiological and/or pathological angiogenic
agent effective through an endogenous nicotinic cholinergic
pathway in endothelial cells and in part by activation of
endothelial–monocyte interactions involved in arteriogenesis.25
Despite this stimulating effect on collateralization, other clinical
studies revealed that smoking was negatively and independently
correlated with reduced coronary collateralization26,27 particularly
in diabetic patients.26 Although diabetes was a signiﬁcant
predictor of adverse left ventricular remodelling in our univariate
model, it was not signiﬁcant in our multivariate model, which
could be the result of loss of cardio-protection in diabetics with
smoking. Although diabetes is well known CAD risk factor, some
endo/exogenous protective mechanisms including ischemic pre-
conditioning might be more effective in some diabetic patients.28–
30 However, the concomitant presence of diabetes and current
smoking as a deadly duet may impair the collateral development
and prevent endogenous cardio-protective mechanisms.26,31–33
Thirdly, acute coronary artery obstructions in individuals, who
smoke are likely greater thrombogenic and less atherogenic than
those of non-smokers.8 Therefore, the smokers have been shown to
have a higher proportion of single vessel disease at the diagnosis of
STEMI than non-smokers, and this paradox can be explained in part
by their less atherosclerotic plaque burden in smokers.8 Moreover,
smokers have a higher risk of sudden cardiac death before hospital
admission compared with non-smokers,34 and the apparent
decrease in case fatality in smokers after an acute cardiac event
is restricted to admitted patients.35 Thus, the ‘smoker’s paradox’
may be largely explained by a greater case fatality before
admission to hospital in smokers.10 Therefore, the apparent
smoker’s paradox seen in early phase of hospitalization should
be interpreted with caution. Moreover, the vast majority of these
studies did not include appropriate adjustment for confounding
factors and were based on secondary analyses of data derived in
randomized trials, which had enrolled highly selected populations.
Of the patients suffering from STEMI, smokers are more than
10 years younger than non-smokers requiring coronary revascu-
larization at a much younger age, which may be a major
confounding factor causing ‘smoker’s paradox.36,37 After adjusting
for differences in age, most studies did not reveal any protective
effect of smoking on cardiovascular outcomes following PCI.12,37,38
This study has some limitations. Because of small size of study
population, we could ﬁnd no evidence to support these ﬁndings
with clinical endpoint. Second, there may have been other factors
interlinked with smoking behavior that we did not record. For
example, smoking cessation could be accompanied with other lifestyle changes such as a diet. Another explanation could be
selection bias since many smokers tend to die of fatal MIs before
they had any chance to undergo PCI.
Studies demonstrate that many hospitals do not consistently
offer tobacco use interventions to their patients.36 This vexing
problem is currently being addressed by the Joint Commission for
Smoking Cessation.39 Whereas persistent smokers in the presence
of established coronary artery disease have an increased risk of re-
infarction and sudden cardiac death, even after coronary revascu-
larization with PCI or bypass grafting,40 many CS-mediated
prothrombotic changes are quickly reversible upon CS cessation.41
This message needs to be disseminated to patients, primary and
secondary care physicians, and the general population. Public
health efforts should urgently promote our understanding of
current CS-induced cardiovascular pathology to encourage indi-
viduals to reduce their exposure to CS. Therefore, it is important to
inquire about smoking status at each clinical encounter, and
appropriate advice should be offered to help patients to stop CS.
We believe that the ‘‘smoker’s paradox’’ is in fact a pseudo-paradox
in STEMI patient undergoing p-PCI; however, further studies with
larger numbers may be warranted.
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